Skip to main content

Advertisement

SpringerLink
Log in

Assessment of linezolid prescriptions in three French hospitals

  • Original Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

The use of linezolid to treat gram-positive cocci infections is increasing in France. Linezolid is approved in pneumonia and complicated skin and soft tissue infections. Overuse and misuse of linezolid can favor the emergence and spreading of linezolid-resistant strains. We aimed to assess the appropriateness of linezolid use in French hospitals. This is a multicenter, retrospective study conducted in three tertiary care hospitals. Appropriateness of linezolid indications and adequacy (composite score concerning dosage, route of administration and blood monitoring) were assessed. Over a three-month period, all prescriptions of linezolid were extracted and analyzed by two independent infectious disease experts. Among the 81 initial prescriptions that were evaluated, indication was appropriate in 48% of cases. Among those, 51% complied with international guidelines. Fifty-seven percent of the prescriptions were adequate regarding dosage, route of administration and blood monitoring. Overall, 23% of prescriptions combined both appropriateness and adequacy. The most frequent reasons for inappropriateness were the possibility of choosing narrower-spectrum antibiotics and the empirical use of linezolid in severe sepsis or septic shock. Initial treatment was the most frequently appropriate in bone and joint infection cases (p = 0.001). Our study shows that even if modalities of use were mostly correct, appropriateness of linezolid indications is low. Educational programs are mandatory to improve practices, as well as clinical studies to better assess the efficacy and safety of linezolid in clinical situations other than pneumonia or complicated skin and soft tissue infections.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. European Centre for Disease Prevention and Control (2014) Antimicrobial resistancesurveillance in Europe.Annual report of the European AntimicrobialResistance Surveillance Network (EARS-Net). Available at: http://ecdc.europa.eu/en/publications/publications/antimicrobial-resistance-europe-2014.pdf. Accessed 24 July 2016

  2. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y (2003) Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36:53–59

    Article  PubMed  Google Scholar 

  3. Zarb P, Coignard B, Griskeviciene J et al. (2012) The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use. Euro Surveill 17(46)

  4. Grau S, Fondevilla E, Freixas N et al (2015) Relationship between consumption of MRSA-active antibiotics and burden of MRSA in acute care hospitals in Catalonia. Spain J Antimicrob Chemother 70:1193–1197

    CAS  PubMed  Google Scholar 

  5. Hawser SP, Bouchillon SK, Hoban DJ, Dowzicky M, Babinchak T (2011) Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004–2009. Int J Antimicrob Agents 37:219–224

    Article  CAS  PubMed  Google Scholar 

  6. Wang G, Hindler JF, Ward KW, Bruckner DA (2006) Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 44:3883–3886

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC (2008) Vancomycin-resistant Staphylococcus aureus in the United States, 2002–2006. Clin Infect Dis 46:668–674

    Article  CAS  PubMed  Google Scholar 

  8. Pofelski J, Pavese P, Brion J-P et al (2003) Staphylococcus aureus meningitis with intermediate sensitivity to glycopeptides. Therapeutic indications. Presse Médicale Paris Fr 1983 32:217–220

    CAS  Google Scholar 

  9. van Hal SJ, Paterson DL (2011) Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother 55:405–410

    Article  PubMed  Google Scholar 

  10. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42:2398–2402

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Lodise TP, Graves J, Evans A et al (2008) Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52:3315–3320

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Estes KS, Derendorf H (2010) Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Eur J Med Res 15:533–543

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Li Z, Willke RJ, Pinto LA et al (2001) Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy 21:263–274

    Article  CAS  PubMed  Google Scholar 

  14. MacGowan AP (2003) Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with gram-positive infections. J Antimicrob Chemother 51(Suppl 2):ii17–25

    CAS  PubMed  Google Scholar 

  15. Tsiodras S, Gold HS, Sakoulas G et al (2001) Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet Lond Engl 358:207–208

    Article  CAS  Google Scholar 

  16. Gales AC, Sader HS, Andrade SS, Lutz L, Machado A, Barth AL (2006) Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int J Antimicrob Agents 27:300–302

    Article  CAS  PubMed  Google Scholar 

  17. Ramírez E, Gómez-Gil R, Borobia AM et al (2013) Improving linezolid use decreases the incidence of resistance among gram-positive microorganisms. Int J Antimicrob Agents 41:174–178

    Article  PubMed  Google Scholar 

  18. Quan H, Sundararajan V, Halfon P et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130–1139

    Article  PubMed  Google Scholar 

  19. Liu C, Bayer A, Cosgrove SE et al (2011) Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52:e18–55

    Article  PubMed  Google Scholar 

  20. Garau J, Bouza E, Chastre J, Gudiol F, Harbarth S (2009) Management of methicillin-resistant Staphylococcus aureus infections. Clin Microbiol Infect 15:125–136

    Article  CAS  PubMed  Google Scholar 

  21. Wunderink RG, Niederman MS, Kollef MH et al (2012) Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 54:621–629

    Article  CAS  PubMed  Google Scholar 

  22. Chastre J, Blasi F, Masterton RG, Rello J, Torres A, Welte T (2014) European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect 20(Suppl 4):19–36

    Article  CAS  PubMed  Google Scholar 

  23. Fu J, Ye X, Chen C, Chen S (2013) The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infections. PLoS One 8:e58240

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Walkey AJ, O’Donnell MR, Wiener RS (2011) Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest 139:1148–1155

    Article  CAS  PubMed  Google Scholar 

  25. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ (2004) Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 43:925–942

    Article  CAS  PubMed  Google Scholar 

  26. Lodise TP, Drusano GL, Zasowski E et al (2014) Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? Clin Infect Dis 59:666–675

    Article  CAS  PubMed  Google Scholar 

  27. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL (2009) Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 49:507–514

    Article  CAS  PubMed  Google Scholar 

  28. van Hal SJ, Paterson DL, Lodise TP (2013) Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 57:734–744

    Article  PubMed  PubMed Central  Google Scholar 

  29. Moellering RC (2012) MRSA: the first half century. J Antimicrob Chemother 67:4–11

    Article  CAS  PubMed  Google Scholar 

  30. Mendes RE, Hogan PA, Streit JM, Jones RN, Flamm RK (2014) Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004–12). J Antimicrob Chemother 69:1582–1588

    Article  CAS  PubMed  Google Scholar 

  31. Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM (2013) The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother 68:4–11

    Article  CAS  PubMed  Google Scholar 

  32. Chauhan D, Mason A (2008) Factors affecting the uptake of new medicines in secondary care—a literature review. J Clin Pharm Ther 33:339–348

    Article  CAS  PubMed  Google Scholar 

  33. Kollef MH, Sherman G, Ward S, Fraser VJ (1999) Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462–474

    Article  CAS  PubMed  Google Scholar 

  34. Dellinger RP, Levy MM, Rhodes A et al (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228

    Article  CAS  PubMed  Google Scholar 

  35. Beekmann SE, Gilbert DN, Polgreen PM, Emerging Infections Network IDSA (2008) Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey. Diagn Microbiol Infect Dis 62:407–410

    Article  CAS  PubMed  Google Scholar 

  36. Conte JE, Golden JA, Kipps J, Zurlinden E (2002) Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 46:1475–1480

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Chavanet P (2013) The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia. Médecine Mal Infect 43:451–455

    Article  CAS  Google Scholar 

  38. Nemeth J, Oesch G, Kuster SP (2015) Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis. J Antimicrob Chemother 70:382–395

    Article  CAS  PubMed  Google Scholar 

  39. Dong H, Xie J, Wang T et al (2016) Pharmacokinetic/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients. Int J Antimicrob Agents 48:259–264

    Article  CAS  PubMed  Google Scholar 

  40. Holland TL, Arnold C, Fowler VG (2014) Clinical management of Staphylococcus aureus bacteremia: a review. JAMA 312:1330–1341

    Article  PubMed  PubMed Central  Google Scholar 

  41. Shorr AF, Kunkel MJ, Kollef M (2005) Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 56:923–929

    Article  CAS  PubMed  Google Scholar 

  42. Conly J (1998) Controlling antibiotic resistance by quelling the epidemic of overuse and misuse of antibiotics. Can Fam Physician 44:1769–1773, 1780–1784

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Méan M, Pavese P, Vittoz JP et al (2006) Prospective assessment of fluoroquinolone use in a teaching hospital. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc ClinMicrobiol 25:757–763

    Article  Google Scholar 

  44. Patel DA, Shorr AF, Chastre J et al (2014) Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Crit Care Lond Engl 18:R157

    Article  Google Scholar 

  45. Mullins CD, Kuznik A, Shaya FT et al (2006) Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Ther 28:1184–1198

    Article  CAS  PubMed  Google Scholar 

  46. Estes L, Orenstem R (2007) Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Ther 29:759-760-761

  47. Wilke MH (2010) Multiresistant bacteria and current therapy—the economical side of the story. Eur J Med Res 15:571–576

    Article  PubMed  PubMed Central  Google Scholar 

  48. Rao N, Ziran BH, Hall RA, Santa ER (2004) Successful treatment of chronic bone and joint infections with oral linezolid. Clin Orthop 67–71

  49. Falagas ME, Siempos II, Papagelopoulos PJ, Vardakas KZ (2007) Linezolid for the treatment of adults with bone and joint infections. Int J Antimicrob Agents 29:233–239

    Article  CAS  PubMed  Google Scholar 

  50. Moran GJ, Krishnadasan A, Gorwitz RJ et al (2006) Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355:666–674

    Article  CAS  PubMed  Google Scholar 

  51. McNicholas S, Barber A, Corbett-Feeney G, Cormican M (2006) Linezolid audit: similarities and contrasts with published experience. J Antimicrob Chemother 57:1008–1009

    Article  CAS  PubMed  Google Scholar 

  52. Ziglam HM, Elliott I, Wilson V, Hill K, Nathwani D (2005) Clinical audit of linezolid use in a large teaching hospital. J Antimicrob Chemother 56:423–426

    Article  CAS  PubMed  Google Scholar 

  53. Walker S, Dresser L, Becker D, Scalera A (2006) An assessment of linezolid utilization in selected Canadian provinces. Can J Infect Dis 17:177–182

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France

    C. Dentan, O. Epaulard & P. Pavese

  2. Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Métropole Savoie, Chambéry, France

    E. Forestier

  3. Pharmacologie, Université Grenoble Alpes; Pôle Recherche, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France

    M. Roustit

  4. Laboratoire de Bactériologie-Hygiène, Institut de Biologie et de Pathologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France

    S. Boisset

  5. Laboratoire TIMC-IMAG, UMR 5525 CNRS, Université Grenoble Alpes, Grenoble, France

    S. Boisset

  6. Institute of Advanced Biosciences (IAB), Centre de Recherche UGA – INSERM U1209 – CNRS UMR 5309, Université Grenoble Alpes, Grenoble, France

    S. Chanoine

  7. Pôle Pharmacie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France

    S. Chanoine

Authors
  1. C. Dentan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Forestier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Roustit
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Boisset
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Chanoine
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. O. Epaulard
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. Pavese
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Dentan.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dentan, C., Forestier, E., Roustit, M. et al. Assessment of linezolid prescriptions in three French hospitals. Eur J Clin Microbiol Infect Dis 36, 1133–1141 (2017). https://doi.org/10.1007/s10096-017-2900-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-017-2900-4

Keywords

Search

Navigation